OpGen, Inc. (OPGN)

NASDAQ: OPGN · IEX Real-Time Price · USD
0.387
-0.002 (-0.49%)
At close: May 20, 2022 4:00 PM
0.399
0.012 (3.101%)
After-hours:May 20, 2022 5:45 PM EDT
Market Cap18.02M
Revenue (ttm)3.95M
Net Income (ttm)-33.93M
Shares Out46.56M
EPS (ttm)-0.83
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume318,671
Open0.390
Previous Close0.389
Day's Range0.380 - 0.410
52-Week Range0.310 - 3.720
Beta-0.51
AnalystsBuy
Price Target3.57 (+822.5%)
Earnings DateMay 12, 2022

About OPGN

OpGen, Inc., a precision medicine company, engages in developing and commercializing molecular microbiology solutions in the United States and internationally. Its product portfolio includes Acuitas AMR Gene Panel, an in vitro diagnostic (IVD) test for the detection and identification of various bacterial nucleic acids and genetic determinants of antimicrobial resistance (AMR) from bacterial colonies isolated from any specimen, as well as Curetis CE-IVD-marked polymerase chain reaction-based SARS-CoV-2 test kits. The company's products also com...

IndustryBiotechnology
IPO DateMay 5, 2015
CEOOliver Schacht
Employees91
Stock ExchangeNASDAQ
Ticker SymbolOPGN
Full Company Profile

Financial Performance

In 2021, OpGen's revenue was $4.31 million, an increase of 2.17% compared to the previous year's $4.21 million. Losses were -$34.81 million, 32.8% more than in 2020.

Financial Statements

Analyst Forecast

According to 8 analysts, the average rating for OPGN stock is "Buy." The 12-month stock price forecast is 3.57, which is an increase of 822.48% from the latest price.

Price Target
$3.57
(822.48% upside)
Analyst Consensus: Buy
Stock Forecasts

News

OpGen, Inc. (OPGN) Reports Q1 Loss, Lags Revenue Estimates

OpGen, Inc. (OPGN) delivered earnings and revenue surprises of 6.25% and 55.24%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

1 week ago - Zacks Investment Research

OpGen Reports First Quarter 2022 Financial Results and Provides Business Update

ROCKVILLE, Md., May 12, 2022 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen” or “the Company”), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to he...

1 week ago - GlobeNewsWire

OpGen to Provide Business Update and Financial Results for the First Quarter 2022 on May 12th at 4:30 p.m. Eastern Time

ROCKVILLE, Md., April 28, 2022 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ: OPGN) (“OpGen” or “the Company”) announced today that the Company will provide a business update and report its first quarter 2022...

3 weeks ago - GlobeNewsWire

OpGen's Subsidiary Curetis and European Investment Bank Plan to Restructure Debt Repayment

ROCKVILLE, Md., April 25, 2022 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen”), a precision medicine company harnessing the power of molecular diagnostics and informatics to help combat infectio...

3 weeks ago - GlobeNewsWire

OpGen's Subsidiary Ares Genetics Commercially Launches New Sequencing and Analysis Services Globally

New services include pathogen identification, microbiome profiling and rapid turnaround sequencing of clinical isolates New services include pathogen identification, microbiome profiling and rapid turna...

1 month ago - GlobeNewsWire

OpGen's subsidiary Ares Genetics provides update on collaboration agreement to drive cutting-edge digital solutions i...

ROCKVILLE, Md., April 06, 2022 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen”), a precision medicine company harnessing the power of molecular diagnostics and informatics to help combat infectio...

1 month ago - GlobeNewsWire

OpGen Announces Interim Analysis Results from Clinical Trial for Unyvero Urinary Tract Infection Panel

ROCKVILLE, Md., April 05, 2022 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen” or “the Company”), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to ...

1 month ago - GlobeNewsWire

OpGen, Inc. (OPGN) Reports Q4 Loss, Tops Revenue Estimates

OpGen, Inc. (OPGN) delivered earnings and revenue surprises of -118.75% and 1.86%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

1 month ago - Zacks Investment Research

OpGen Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update

ROCKVILLE, Md., March 29, 2022 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen” or “the Company”), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to ...

1 month ago - GlobeNewsWire

OpGen to Provide Business Update and Financial Results for the Fourth Quarter and Full Year 2021 on March 29th at 4:3...

ROCKVILLE, Md., March 15, 2022 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ: OPGN) (“OpGen” or “the Company”) announced today that the Company will provide a business update and report its fourth quarter and...

2 months ago - GlobeNewsWire

OpGen Announces Publication of Results from the Acuitas AMR Gene Panel Multicenter Clinical Trial in the Journal of C...

ROCKVILLE, Md., Feb. 10, 2022 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen”), a precision medicine company harnessing the power of molecular diagnostics and informatics to help combat infectiou...

3 months ago - GlobeNewsWire

OpGen Announces Successful Completion of Unyvero A30 Development Milestone

ROCKVILLE, Md., Feb. 10, 2022 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen”), a precision medicine company harnessing the power of molecular diagnostics and informatics to help combat infectiou...

3 months ago - GlobeNewsWire

OpGen to Participate in Edison Group's Global Healthcare “Open House” Virtual Conference from January 25-27th, 2022

ROCKVILLE, Md., Jan. 18, 2022 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen”), a precision medicine company harnessing the power of molecular diagnostics and informatics to help combat infectiou...

4 months ago - GlobeNewsWire

OpGen Announces Preliminary Unaudited Revenue for Fiscal 2021 and Provides Business Update

ROCKVILLE, Md., Jan. 10, 2022 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen”), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infect...

4 months ago - GlobeNewsWire

OpGen subsidiary Ares Genetics announces the strategic expansion of ARESdb proprietary contents

ROCKVILLE, Md., Dec. 14, 2021 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen” or the “Company”), a precision medicine company harnessing the power of molecular diagnostics and informatics to help...

5 months ago - GlobeNewsWire

OpGen Announces Results of Special Meeting of Stockholders

ROCKVILLE, Md., Dec. 08, 2021 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen” or the “Company”), a precision medicine company harnessing the power of molecular diagnostics and informatics to help...

5 months ago - GlobeNewsWire

OpGen Subsidiary Ares Genetics Announces Strategic Database Access Transaction

ROCKVILLE, Md., Nov. 30, 2021 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen”), a precision medicine company harnessing the power of molecular diagnostics and informatics to help combat infectiou...

5 months ago - GlobeNewsWire

5 Penny Stocks To Buy Now According To Insiders In November 2021

Hot penny stocks insiders are buying in November The post 5 Penny Stocks To Buy Now According To Insiders In November 2021 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStock...

Other symbols:CMPXLQDAOEGPETV
6 months ago - PennyStocks

OpGen Reports Third Quarter 2021 Financial Results and Provides Business Update

Conference call to be held at 4:30 p.m. Eastern Standard Time today

6 months ago - GlobeNewsWire

OpGen, Inc. (OPGN) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

OpGen, Inc. (OPGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

6 months ago - Zacks Investment Research

OpGen Appoints Albert Weber as Chief Financial Officer

ROCKVILLE, Md., Nov. 04, 2021 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen” or the “Company”), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to h...

6 months ago - GlobeNewsWire

OpGen Announces Special Meeting of Stockholders to Vote on Proposed Increase to Number of Authorized Shares of Common...

ROCKVILLE, Md., Nov. 04, 2021 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen” or the “Company”), a precision medicine company harnessing the power of molecular diagnostics and informatics to help...

6 months ago - GlobeNewsWire

OpGen to Provide Business Update and Financial Results for the Third Quarter 2021 on November 11th at 4:30 p.m. Easte...

ROCKVILLE, Md., Oct. 28, 2021 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ: OPGN) (“OpGen” or “the Company”) announced today that the Company will provide a business update and report its third quarter 2021 ...

6 months ago - GlobeNewsWire

OpGen Subsidiary Ares Genetics Launches AREScloud

ROCKVILLE, Md., Oct. 21, 2021 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen”), a precision medicine company harnessing the power of molecular diagnostics and informatics to help combat infectiou...

7 months ago - GlobeNewsWire

OpGen Announces Closing of $15 Million Registered Direct Offering

ROCKVILLE, Md., Oct. 18, 2021 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen” or the “Company”), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to h...

7 months ago - GlobeNewsWire